Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy

Journal of Clinical Oncology

Volumn 23, Issue 31, 2005, Pages 7904-7910

  Tu, Shi Ming ^a   Kim, Jeri ^a   Pagliaro, Lance C ^a   Vakar Lopez, Funda ^a   Wong, Frankin C ^a   Wen, Sijin ^a   General, Rosales ^a   Podoloff, Donald A ^a   Lin, Sue Hwa ^a   Logothetis, Christopher J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ATRASENTAN; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DIETHYLSTILBESTROL; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ETOPOSIDE; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; GAMMA INTERFERON; GBC 590; GEMCITABINE; IFOSFAMIDE; IMATINIB; KETOCONAZOLE; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; PECTIN; STRONTIUM 89; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC ANTIBIOTIC; STRONTIUM;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW BIOPSY; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CARDIOMYOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN TISSUE; MALE; MYELODYSPLASTIC SYNDROME; PATIENT ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE DRUG DOSE; SPINAL CORD COMPRESSION; TREATMENT DURATION; TREATMENT RESPONSE; BONE MARROW; BONE TUMOR; DRUG EFFECT; MAXIMUM TOLERATED DOSE; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM; PALLIATIVE THERAPY; PATHOLOGY; PROSTATE TUMOR; RADIATION EXPOSURE; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; BONE MARROW; BONE NEOPLASMS; COMBINED MODALITY THERAPY; DOXORUBICIN; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PALLIATIVE CARE; PROSTATIC NEOPLASMS; STRONTIUM RADIOISOTOPES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 32944474117     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.2310     Document Type: Article

References (22)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer statistics, 2001. CA Cancer J Clin 51:15-36, 2001
2. [Erratum: CA Cancer J Clin 51:144, 2001]
3. Ben-Josef E, Lucas DR, Vasan S, et al: Selective accumulation of strontium-89 in metastatic deposits in bone: Radio-histological correlation. Nucl Med Commun 16:457-463, 1995
4. Robinson RG, Spicer JA, Blake GM, et al: Strontium-89: Treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 9:271-281, 1989
5. Nightengale B, Brune M, Blizzard SP, et al: Strontium chloride Sr89 for treating pain from metastatic bone disease. Am J Health Syst Pharm 52:2189-2195, 1995
6. Powsner RA, Zietman AL, Foss FM: Bone marrow suppression after strontium-89 therapy and local radiation therapy in patients with diffuse marrow involvement. Clin Nucl Med 22:147-150, 1997
7. Tu SM, Millikan RE, Mengistu B, et al: Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomized phase II trial. Lancet 357:336-341, 2001
8. Ellerhorst JA, Tu SM, Amato RJ, et al: Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3:2371-2376, 1997
9. Tu SM, Delpassand ES, Jones D, et al: Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer. Urol Oncol 2:191-197, 1996
10. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-461, 1958
11. Kossman S, Weiss M: Acute myelogenous leukemia after exposure to strontium-89 for adenocarcinoma of the prostate. Cancer 88:620-624, 2000
12. Daliani DD, Assikis V, Tu SM, et al: Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer 97:561-567, 2003
13. Mathew P, Thall PF, Jones D, et al: Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: A modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 22:3323-3329, 2004
14. Herbst RS, Madden TL, Tran HT, et al: Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: Evidence for activity in non-small-cell lung cancer. J Clin Oncol 20:4440-4447, 2002
15. Thall PF, Millikan RE, Sung HG: Evaluating multiple treatment courses in clinical trials. Stat Med 19:1011-1028, 2000
16. Porter AT, McEwan AJB, Powe JE, et al: Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25:805-813, 1993
17. Serafini AN, Houston SJ, Resche I, et al: Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial. J Clin Oncol 16:1574-1581, 1998
18. Sartor O, Reid RH, Hoskins PJ, et al: Samarium-153 lexidronam complex for treatment of painful bone metastases in hormone refractory prostate cancer. Urology 63:940-945, 2004
19. Han SH, de Klerk JMH, Tan S, et al: The placorhen study: A double-blind, placebo-controlled, randomized radionuclide study with 186-Re-etidronate in hormone-resistant prostate cancer patients with painful metastases. J Nucl Med 43:1150-1156, 2002
20. Quilty PM, Kirk D, Bolger JJ, et al: A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 31:33-40, 1994
21. Sciuto R, Festa A, Rea S, et al: Effects of low-dose cisplatin on Sr-89 therapy for painful bone metastases from prostate cancer: A randomized clinical trial. J Nucl Med 43:79-86, 2002
22. Imedo H, Manka-Waluch A, Albers P, et al: Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: Randomized phase II trial with the new, high-energy radiopharmaceutical Rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 21:2869-2875, 2003